CF1

10.0%

2.2¢ complii fintech solutions ltd

Option conversion, page-2

First 2 Last

Share
Profile

Follow
211461

920 Posts.

30

05/12/17

09:53

Post #: 29372507
Share

Originally posted by BottleShock ↑

Received my Expiry of Options letter this morning (and yes, I will be exercising mine) and it prompted me to run some numbers to see if I could take a guess at the likely take up rate.

At the time of resting there were 302 million options issued to the market (I've rounded the numbers to make it easier). Based on my expiry letter as of 29 November 2017 240 million remained "unexercised". That means 62 million have been exercised at .008 which has contributed just shy of $500K to Intiger's cashflow in the last couple of years.

Now what of the remaining options? Given the relative illiquidity of the options in the last 2 years I suspect there are quite a view large IAMOA holders (myself included) who to various degrees are in red and need to make the call on whether they try to bail out now at a substantial loss or bite the bullet and convert them. That's going to very much a personal decision based on each individuals view of where Initiger's share price is heading in the future. There will probably be plenty of fresh buyers who will see the options "in the money" in the next couple of weeks to let this happen and in turn convert them.

That leaves the 179 million options that have been traded at .01 or under since the 11th of August. A great many of those would have just been churn (the same parcels being passed around) however in my opinion given the current SP and business momentum these stand a very good chance of being exercised.

So where does that leave us? I'll take a punt and guess that something like 200 million options will be exercised at .008 giving Intiger around $1.6M extra to play with going into 2018. Yes, that means the SP may feel some initial pressure due to the dilution but in my opinion that will soon be forgotten. If that many options do get exercised the subsequent trading volumes will likely be quite high and if that is coupled with a couple of decent announcements and a reasonable 4C release at the end of January the worst will most certainly be behind us.
.

Expand

The old, the next 4C will be better trick.

IAM Price at posting: 1.4¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BUX

Buxton projects new graphite province discovery at WA Narryer play

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

There are more pages in this discussion • 5 more messages in this thread...

First 2 Last

Add CF1 (ASX) to my watchlist

(20min delay)
Last 2.2¢		Change 0.002(10.0%)		Mkt cap ! $12.58M

Open	High	Low	Value	Volume
2.1¢	2.2¢	2.1¢	$7.78K	360.6K

Buyers (Bids)

No.	Vol.	Price($)
1	103090	2.2¢

Sellers (Offers)

Price($)	Vol.	No.
2.3¢	300000	1

View Market Depth

No.	Vol.	Price($)
1	491617	0.020
1	200000	0.019
3	1434231	0.018
1	1000000	0.017
1	1000000	0.016

Price($)	Vol.	No.
0.023	300000	1
0.024	125000	1
0.026	64744	1
0.028	483161	1
0.030	827135	4

Last trade - 15.54pm 04/10/2024 (20 minute delay)

CF1 (ASX) Chart

Option conversion, page-2

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Buxton projects new graphite province discovery at WA Narryer play

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI reaches close of funding facility for salt-first part of Mardie project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Option conversion, page-2

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Buxton projects new graphite province discovery at WA Narryer play

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI reaches close of funding facility for salt-first part of Mardie project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News